Interview: Akari's Coversin Ticking Along Nicely
Phase II Trial Shows Promise For Rare Skin Disorder
Executive Summary
The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.
You may also be interested in...
The Game Looks Up For Galecto
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
What Verona Needs To Make COPD Drug Ensifentrine A Success
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.